[
    [
        {
            "time": "",
            "original_text": "【太平洋医药】大参林19年报&20Q1点评：20Q1利润增速超预期，整体平效持续提升",
            "features": {
                "keywords": [
                    "大参林",
                    "19年报",
                    "20Q1",
                    "利润增速",
                    "超预期",
                    "平效提升"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【太平洋医药】大参林19年报&20Q1点评：20Q1利润增速超预期，整体平效持续提升",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]